Karuna Therapeutics Schedules Webcast and Conference Call to Announce Results from its Phase 2 Clinical Trial of KarXT for the Treatment of Psychosis in Patients with Schizophrenia
Go back to Karuna Therapeutics Schedules Webcast and Conference Call to Announce Results from its Phase 2 Clinical Trial of KarXT for the Treatment of Psychosis in Patients with Schizophrenia| (NASDAQ: KRTX) | Delayed: 329.83 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $329.83 | 52 Week High | $ | |||
| Open | $25.31 | 52 Week Low | $ | |||
| Day High | $329.83 | P/E | N/A | |||
| Day Low | $329.83 | EPS | $ | |||
| Volume | 9 | |||||
